UBS has restated its recommendation to buy Edenred, but has lowered its target price to €50 from €66. This new target suggests a potential increase of 44%.
The adjustment is in line with the company's projections for 2024, which now anticipate EBITDA between €1.23 billion and €1.3 billion, up from €1.09 billion in 2023.
Edenred has also reaffirmed its objective of surpassing total revenues of €5 billion by 2030, demonstrating its commitment to growth in the future. Investors should take these updated figures into account when evaluating their positions in the company.